Day One

Wednesday, 27th January 2021

Day Two

Thursday, 28th January 2021

All times displayed in EST - for PST, please see the Full Event Guide

8:30 am Morning Networking

Synopsis

Grab a quick cup of tea or coffee from the comfort of your own home office and jump straight into your opportunity to connect with new contacts from active companies in the field and exchange digital business cards. Network and form lasting connections through this exclusive virtual speed networking!

9:00 am Opening Remarks from the Chair

Developing Clinically-Relevant Antigen-Specific Tolerogenic Approaches

9:10 am Panel: What Progress Has There Been in Achieving Antigen Specific Therapeutics

  • Simi Ahmed Director of Research & Lead of the Immune Therapies Program, JDRF
  • Jose Carballido Executive Director (Translational Medicine/ Preclinical Safety), Novartis
  • David Wraith Founder & Chief Scientific Officer – Apitope; Director, Institute of Immunology & Immunotherapy, University of Birmingham

10:00 am Success Story: Gliadin-Encapsulating Nanoparticles Induce Gluten-Specific Tolerance in Celiac Disease – Results of A Phase 1/ 2 Placebo-Controlled Clinical Trial

  • Ciaran P. Kelly Professor of Medicine/Chief/Director/Medical Director, Harvard Medical School/Herman L. Blumgart Internal Medicine Firm/Gastroenterology Fellowship Training/Celiac Center

10:30 am Challenges in Defining & Measuring Immunological Tolerance in the Long Term

11:00 am Digital Speed Networking

Immune Tolerance using Gene Therapy Approaches

11:40 am Challenges and Opportunities for Immune Tolerance Induction in AAV Gene Therapy

Bringing Antigen Specific Immune Tolerance Therapies to The Clinic

12:10 pm Developing Robust Data to Valid MoA & Demonstrate Clinical Proof of Concept

  • David Wraith Founder & Chief Scientific Officer – Apitope; Director, Institute of Immunology & Immunotherapy, University of Birmingham

12:40 pm Lunch & Digital Speed Networking

1:40 pm Developing Suitable Preclinical Models to Enable Successful Clinical Translation

  • Dr Bruce Mazer Associate Scientific Director, Strategy , Canadian Covid-19 Immunity Task Force

2:10 pm Induction of cytolytic phenotype in human and mouse CD4+ T-cells by MOG-derived Imotopes™ and validation of the immunosuppressive capacity in mouse models of Multiple Sclerosis

2:40 pm Developing Biomarker Assays that Can Inform Both Target Engagement & Pharmacodynamic Effects

  • Brendan Classon Vice President Research & Development, Parvus Therapeutics

3:10 pm Networking break

3:40 pm Biomarker-Driven Trial Design and Patient Stratification for Clinical Trials

4:10 pm Cell Squeezing RBCs to Create Therapy for Inducing Antigen- Specific Tolerance

  • Shinu John Associate Director, Immune Tolerance, SQZ Biotechnologies

The Use of Cell Therapy to Induce Immune Tolerance

4:40 pm Directly Targeting Autoantigen-Specific T-Cells

  • Saso Cermerski VP & Head of Discovery & Translational Immunology, Cue Biopharma

5:10 pm Shielded Living Therapeutics (SLTx): A novel allogeneic cell therapy platform for induction of antigen-specific immune tolerance & restoration of immune homeostasis.

5:40 pm Chair’s Closing Remarks

5:45 pm End of Day